Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by New York Life Investment Management LLC

New York Life Investment Management LLC decreased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 7.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,138 shares of the medical research company’s stock after selling 926 shares during the quarter. New York Life Investment Management LLC’s holdings in Charles River Laboratories International were worth $2,241,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CRL. Stephens Inc. AR increased its holdings in shares of Charles River Laboratories International by 126.9% during the third quarter. Stephens Inc. AR now owns 5,463 shares of the medical research company’s stock valued at $1,076,000 after acquiring an additional 3,055 shares in the last quarter. Ground Swell Capital LLC acquired a new position in Charles River Laboratories International during the 3rd quarter valued at approximately $283,000. Principal Financial Group Inc. increased its stake in Charles River Laboratories International by 3.6% during the 3rd quarter. Principal Financial Group Inc. now owns 60,501 shares of the medical research company’s stock valued at $11,917,000 after purchasing an additional 2,126 shares in the last quarter. Assetmark Inc. raised its holdings in shares of Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after buying an additional 173 shares during the last quarter. Finally, Covestor Ltd lifted its stake in shares of Charles River Laboratories International by 40.9% during the third quarter. Covestor Ltd now owns 327 shares of the medical research company’s stock worth $65,000 after buying an additional 95 shares during the period. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Trading Up 0.1 %

Shares of Charles River Laboratories International stock opened at $165.01 on Monday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The stock’s 50 day simple moving average is $170.94 and its 200-day simple moving average is $186.85. The stock has a market cap of $8.44 billion, a P/E ratio of 1,100.04, a P/E/G ratio of 4.54 and a beta of 1.37. Charles River Laboratories International, Inc. has a 1-year low of $150.79 and a 1-year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. During the same quarter in the prior year, the firm posted $2.46 earnings per share. Charles River Laboratories International’s quarterly revenue was down 1.1% on a year-over-year basis. Analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on CRL. Evercore ISI raised their target price on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research note on Thursday, November 7th. UBS Group reaffirmed a “neutral” rating and set a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Morgan Stanley cut their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 5th. Barclays decreased their price objective on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 18th. Finally, William Blair lowered shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. Three research analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, Charles River Laboratories International currently has a consensus rating of “Hold” and an average target price of $195.71.

Insider Activity

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the sale, the executive vice president now owns 20,013 shares of the company’s stock, valued at $3,252,112.50. This trade represents a 18.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO James C. Foster purchased 6,075 shares of the stock in a transaction dated Thursday, February 20th. The shares were acquired at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the acquisition, the chief executive officer now owns 183,639 shares in the company, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).